These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26305034)

  • 1. Prostate cancer: Docetaxel plus ADT significantly improves patient outcomes.
    Sidaway P
    Nat Rev Clin Oncol; 2015 Oct; 12(10):563. PubMed ID: 26305034
    [No Abstract]   [Full Text] [Related]  

  • 2. [Docetaxel for metastatic prostate cancer: early is better].
    Gietema JA; Oosting SF
    Ned Tijdschr Geneeskd; 2016; 160():D215. PubMed ID: 27405569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel for hormone-sensitive metastatic prostate cancer.
    Baker H
    Lancet Oncol; 2015 Sep; 16(9):e432. PubMed ID: 26278160
    [No Abstract]   [Full Text] [Related]  

  • 4. Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials.
    van Soest RJ; de Wit R
    BMC Med; 2015 Dec; 13():304. PubMed ID: 26695172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHAARTED/GETUG 12--docetaxel in non-castrate prostate cancers.
    Teo MY; Scher HI
    Nat Rev Clin Oncol; 2015 Dec; 12(12):687-8. PubMed ID: 26552950
    [No Abstract]   [Full Text] [Related]  

  • 6. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer.
    Voskoboynik M; Staffurth J; Malik Z; Sweeney C; Chowdhury S
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1253-6. PubMed ID: 25353342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
    Gravis G; Fizazi K; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M
    Lancet Oncol; 2013 Feb; 14(2):149-58. PubMed ID: 23306100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will chemotherapy change the management of prostate cancer?
    Gilson C; Sydes MR; Chowdhury S
    BJU Int; 2016 Aug; 118(2):190-2. PubMed ID: 26696125
    [No Abstract]   [Full Text] [Related]  

  • 9. Commentary on "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial." Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Medical Oncology and Biostatistics, Institut Paoli-Calmettes, Marseille, France. Lancet Oncol 2013;14(2):149-58 [Epub 2013 Jan 8].
    Trump DL
    Urol Oncol; 2013 Nov; 31(8):1845. PubMed ID: 24210084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report.
    Rahman F; Rahardjo HE; Ariwicaksono SC; Hafizar H; Sembiring MGA; Andika R; Patandung R; Hidianingsih S; Hotasi SL
    Acta Med Indones; 2017 Jan; 49(1):74-78. PubMed ID: 28450658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.
    Armstrong AJ
    Oncology (Williston Park); 2014 Oct; 28(10):881, 883. PubMed ID: 25323615
    [No Abstract]   [Full Text] [Related]  

  • 12. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer.
    Ciccarese C; Santoni M; Massari F
    N Engl J Med; 2016 Jan; 374(3):286. PubMed ID: 26789884
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer.
    Garcia JA; Sweeney C;
    N Engl J Med; 2016 Jan; 374(3):287. PubMed ID: 26789883
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
    Taneja SS
    J Urol; 2016 Jan; 195(1):94. PubMed ID: 26699961
    [No Abstract]   [Full Text] [Related]  

  • 16. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis.
    Suzman DL; Antonarakis ES
    Oncology (Williston Park); 2014 Oct; 28(10):880, 882. PubMed ID: 25323614
    [No Abstract]   [Full Text] [Related]  

  • 17. Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy.
    Barnett CM; Flamiatos JF; Beer TM
    Anticancer Res; 2011 Mar; 31(3):973-4. PubMed ID: 21498723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A one-two punch against prostate cancer.
    Johns Hopkins Med Lett Health After 50; 2014 Mar; 26(1):8. PubMed ID: 24937853
    [No Abstract]   [Full Text] [Related]  

  • 19. Words of Wisdom. Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
    Murphy DG; Zargar H
    Eur Urol; 2016 Mar; 69(3):540. PubMed ID: 26867727
    [No Abstract]   [Full Text] [Related]  

  • 20. Words of Wisdom. Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
    Mathieu R; Shariat SF
    Eur Urol; 2016 Apr; 69(4):755-6. PubMed ID: 26972499
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.